These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 19939578

  • 1. The impact of acute urinary retention after iodine-125 prostate brachytherapy on health-related quality of life.
    Roeloffzen EM, Hinnen KA, Battermann JJ, Monninkhof EM, van Roermund JG, van Gellekom MP, Frank SJ, van Vulpen M.
    Int J Radiat Oncol Biol Phys; 2010 Aug 01; 77(5):1322-8. PubMed ID: 19939578
    [Abstract] [Full Text] [Related]

  • 2. Health-related quality of life up to six years after (125)I brachytherapy for early-stage prostate cancer.
    Roeloffzen EM, Lips IM, van Gellekom MP, van Roermund J, Frank SJ, Battermann JJ, van Vulpen M.
    Int J Radiat Oncol Biol Phys; 2010 Mar 15; 76(4):1054-60. PubMed ID: 20097486
    [Abstract] [Full Text] [Related]

  • 3. Health-related quality of life in men after treatment of localized prostate cancer with external beam radiotherapy combined with (192)ir brachytherapy: a prospective study of 93 cases using the EORTC questionnaires QLQ-C30 and QLQ-PR25.
    Wahlgren T, Brandberg Y, Häggarth L, Hellström M, Nilsson S.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):51-9. PubMed ID: 15337539
    [Abstract] [Full Text] [Related]

  • 4. Pretreatment nomogram to predict the risk of acute urinary retention after I-125 prostate brachytherapy.
    Roeloffzen EM, van Vulpen M, Battermann JJ, van Roermund JG, Saibishkumar EP, Monninkhof EM.
    Int J Radiat Oncol Biol Phys; 2011 Nov 01; 81(3):737-44. PubMed ID: 20888131
    [Abstract] [Full Text] [Related]

  • 5. Quality of life of patients after permanent prostate brachytherapy in relation to dosimetry.
    Van Gellekom MP, Moerland MA, Van Vulpen M, Wijrdeman HK, Battermann JJ.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):772-80. PubMed ID: 15964707
    [Abstract] [Full Text] [Related]

  • 6. Prospective assessment of patient-reported long-term urinary morbidity and associated quality of life changes after 125I prostate brachytherapy.
    Stone NN, Stock RG.
    Brachytherapy; 2003 Nov 01; 2(1):32-9. PubMed ID: 15062161
    [Abstract] [Full Text] [Related]

  • 7. Promising long-term health-related quality of life after high-dose-rate brachytherapy boost for localized prostate cancer.
    Wahlgren T, Nilsson S, Lennernäs B, Brandberg Y.
    Int J Radiat Oncol Biol Phys; 2007 Nov 01; 69(3):662-70. PubMed ID: 17499452
    [Abstract] [Full Text] [Related]

  • 8. Preimplant predictive factors of urinary retention after iodine 125 prostate brachytherapy.
    Mabjeesh NJ, Chen J, Stenger A, Matzkin H.
    Urology; 2007 Sep 01; 70(3):548-53. PubMed ID: 17905113
    [Abstract] [Full Text] [Related]

  • 9. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05.
    Feigenberg SJ, Lee WR, Desilvio ML, Winter K, Pisansky TM, Bruner DW, Lawton C, Morton G, Baikadi M, Sandler H.
    Int J Radiat Oncol Biol Phys; 2005 Jul 15; 62(4):956-64. PubMed ID: 15989995
    [Abstract] [Full Text] [Related]

  • 10. Health-related quality of life 2 years after treatment with radical prostatectomy, prostate brachytherapy, or external beam radiotherapy in patients with clinically localized prostate cancer.
    Ferrer M, Suárez JF, Guedea F, Fernández P, Macías V, Mariño A, Hervas A, Herruzo I, Ortiz MJ, Villavicencio H, Craven-Bratle J, Garin O, Aguiló F, Multicentric Spanish Group of Clinically Localized Prostate Cancer.
    Int J Radiat Oncol Biol Phys; 2008 Oct 01; 72(2):421-32. PubMed ID: 18325680
    [Abstract] [Full Text] [Related]

  • 11. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H, Yano M, Awa Y, Nakatsu H, Egoshi K, Mikami K, Ota S, Okano T, Hamano S, Ohki T, Furuya Y, Ichikawa T.
    Int J Urol; 2006 Sep 01; 13(9):1202-6. PubMed ID: 16984553
    [Abstract] [Full Text] [Related]

  • 12. Early quality of life assessment in men treated with permanent source interstitial brachytherapy for clinically localized prostate cancer.
    Lee WR, McQuellon RP, Case LD, deGuzman AF, McCullough DL.
    J Urol; 1999 Aug 01; 162(2):403-6. PubMed ID: 10411047
    [Abstract] [Full Text] [Related]

  • 13. Single-fraction high-dose-rate brachytherapy and hypofractionated external beam radiotherapy for men with intermediate-risk prostate cancer: analysis of short- and medium-term toxicity and quality of life.
    Morton GC, Loblaw DA, Sankreacha R, Deabreu A, Zhang L, Mamedov A, Cheung P, Keller B, Danjoux C, Szumacher E, Thomas G.
    Int J Radiat Oncol Biol Phys; 2010 Jul 01; 77(3):811-7. PubMed ID: 19836166
    [Abstract] [Full Text] [Related]

  • 14. Peak flow rate is the best predictor of acute urinary retention following prostate brachytherapy: our experience and literature review.
    Ikeda T, Shinohara K.
    Int J Urol; 2009 Jun 01; 16(6):558-60. PubMed ID: 19456987
    [Abstract] [Full Text] [Related]

  • 15. Health-related quality of life after radical prostatectomy and low-dose-rate brachytherapy for localized prostate cancer.
    Wyler SF, Engeler DS, Seelentag W, Ries G, Schmid HP.
    Urol Int; 2009 Jun 01; 82(1):17-23. PubMed ID: 19172091
    [Abstract] [Full Text] [Related]

  • 16. Influence of dose on risk of acute urinary retention after iodine-125 prostate brachytherapy.
    Roeloffzen EM, Battermann JJ, van Deursen MJ, Monninkhof EM, Visscher MI, Moerland MA, van Vulpen M.
    Int J Radiat Oncol Biol Phys; 2011 Jul 15; 80(4):1072-9. PubMed ID: 20615621
    [Abstract] [Full Text] [Related]

  • 17. Health related quality of life patterns in patients treated with interstitial prostate brachytherapy for localized prostate cancer--data from CaPSURE.
    Downs TM, Sadetsky N, Pasta DJ, Grossfeld GD, Kane CJ, Mehta SS, Carroll PR, Lubeck DP.
    J Urol; 2003 Nov 15; 170(5):1822-7. PubMed ID: 14532784
    [Abstract] [Full Text] [Related]

  • 18. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
    Forsythe K, Blacksburg S, Stone N, Stock RG.
    Int J Radiat Oncol Biol Phys; 2012 Jun 01; 83(2):630-5. PubMed ID: 22099032
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. External validation of the pretreatment nomogram to predict acute urinary retention after (125)I prostate brachytherapy.
    Roeloffzen EM, Crook J, Monninkhof EM, McLean M, van Vulpen M, Saibishkumar EP.
    Brachytherapy; 2012 Jun 01; 11(4):256-64. PubMed ID: 22342573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.